Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pruritus - Overview
Pruritus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus - Companies Involved in Therapeutics Development

9 Meters Biopharma Inc
AfaSci Inc
Akaal Pharma Pty Ltd
Albireo Pharma Inc
Amgen Inc
AntalGenics SL
AOBiome LLC
Asa BioSciences LLC
Avior Bio Inc
BioArdis LLC
Biomimetix JV LLC
Cara Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clexio Biosciences Ltd
DermaXon LLC
DongKoo Bio & Pharma Co Ltd
ELORAC Inc
Escient Pharmaceuticals Inc
Evommune Inc
Genu Pharma Co Ltd
GlaxoSmithKline Plc
Jiangsu Hengrui Medicine Co Ltd
Kiniksa Pharmaceuticals Ltd
Kissei Pharmaceutical Co Ltd
Lumosa Therapeutics Co Ltd
MC2 Therapeutics AS
Mirum Pharmaceuticals Inc
Neurim Pharmaceuticals Ltd
Patagonia Pharmaceuticals LLC
Peptide Logic LLC
Pfizer Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Sanio AB
Sanwa Kagaku Kenkyusho Co Ltd
Shanton Pharma Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sien Biopharmaceuticals Inc
Sunny Pharmtech Inc
Suzhou Connect Biopharmaceuticals Ltd
Teikoku Pharma USA Inc
Tioga Pharmaceuticals Inc
Titan Pharmaceuticals Inc
Toray Industries Inc
Trevi Therapeutics Inc
Vivozon Inc
YIRUI Pharmaceutical Technology Co Ltd
Pruritus - Drug Profiles
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1529 - Drug Profile
Product Description
Mechanism Of Action
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-6120 - Drug Profile
Product Description
Mechanism Of Action
AMG-8379 - Drug Profile
Product Description
Mechanism Of Action
asimadoline - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
AV-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
B-244 - Drug Profile
Product Description
Mechanism Of Action
History of Events
bepotastine SR - Drug Profile
Product Description
Mechanism Of Action
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CBP-174 - Drug Profile
Product Description
Mechanism Of Action
History of Events
detomidine - Drug Profile
Product Description
Mechanism Of Action
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
History of Events
DKB-19003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Block Cav3 and v for Pruritus - Drug Profile
Product Description
Mechanism Of Action
dupilumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
DX-412 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVO-103 - Drug Profile
Product Description
Mechanism Of Action
HPI-1201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSK-21542 - Drug Profile
Product Description
Mechanism Of Action
KNV-0969 - Drug Profile
Product Description
Mechanism Of Action
linerixibat - Drug Profile
Product Description
Mechanism Of Action
History of Events
LT-5001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC-225 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclol Antibody Conjugate to Agonize Kappa Opioid Receptor for Dermatosis, Osteoarthritis Pain and Uremic Pruritus - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRGPRX2 Antagonist - Drug Profile
Product Description
Mechanism Of Action
lbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
lfurafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
loxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
NeuP-12 - Drug Profile
Product Description
Mechanism Of Action
odevixibat - Drug Profile
Product Description
Mechanism Of Action
History of Events
opiranserin - Drug Profile
Product Description
Mechanism Of Action
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
pegcantratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Target TRPV1 for Pain and Pruritus - Drug Profile
Product Description
Mechanism Of Action
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
PR-38 - Drug Profile
Product Description
Mechanism Of Action
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAP-002 - Drug Profile
Product Description
Mechanism Of Action
SHR-0410 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Block v1.8 Sodium Channel for Pain And Pruritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
vixarelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
History of Events
YR-007 - Drug Profile
Product Description
Mechanism Of Action
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Mar 28, 2022: Cara Therapeutics announces Oral KORSUVA (difelikefalin) improves itch and inflammatory biomarkers in atopic dermatitis patients with moderate-to-severe pruritus
Mar 08, 2022: Cara Therapeutics announces oral KORSUVA (difelikefalin) data selected for late-breaking presentation at 2022 American Academy of Dermatology Annual Meeting
Feb 25, 2022: Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Feb 22, 2022: AOBiome Therapeutics’ topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)
Feb 02, 2022: Trevi concludes enrolment of Phase IIb/III itch trial in prurigo nodularis
Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients
Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients
Jan 05, 2022: Enteris BioPharma highlights 2021 achievements and 2022 Outlook
Jan 05, 2022: Albireo increases 2021 Bylvay (odevixibat) sales guidance
Dec 20, 2021: Cara Therapeutics announces CMS grants TDAPA to KORSUVA (difelikefalin) injection
Dec 13, 2021: Albireo presenting new Bylvay (odevixibat) Data at SPGHAN 2021
Nov 16, 2021: AOBiome achieves landmark recruitment goal in largest clinical trial ever powered by a live topical biotherapeutic
Nov 15, 2021: Trevi Therapeutics to present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
Nov 12, 2021: Albireo announces new phase 3 data for Bylvay (odevixibat) in PFIC and first reveal of new next generation bile acid modulator data at AASLD The Liver Meeting 2021
Nov 05, 2021: Titan announces upcoming TP-2021 Implant data presentation at Neuroscience 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Pruritus, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Pruritus, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pruritus - Pipeline by 9 Meters Biopharma Inc, 2022
Pruritus - Pipeline by AfaSci Inc, 2022
Pruritus - Pipeline by Akaal Pharma Pty Ltd, 2022
Pruritus - Pipeline by Albireo Pharma Inc, 2022
Pruritus - Pipeline by Amgen Inc, 2022
Pruritus - Pipeline by AntalGenics SL, 2022
Pruritus - Pipeline by AOBiome LLC, 2022
Pruritus - Pipeline by Asana BioSciences LLC, 2022
Pruritus - Pipeline by Avior Bio Inc, 2022
Pruritus - Pipeline by BioArdis LLC, 2022
Pruritus - Pipeline by Biomimetix JV LLC, 2022
Pruritus - Pipeline by Cara Therapeutics Inc, 2022
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Clexio Biosciences Ltd, 2022
Pruritus - Pipeline by DermaXon LLC, 2022
Pruritus - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Pruritus - Pipeline by ELORAC Inc, 2022
Pruritus - Pipeline by Escient Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Evommune Inc, 2022
Pruritus - Pipeline by Genu Pharma Co Ltd, 2022
Pruritus - Pipeline by GlaxoSmithKline Plc, 2022
Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pruritus - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Pruritus - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Lumosa Therapeutics Co Ltd, 2022
Pruritus - Pipeline by MC2 Therapeutics AS, 2022
Pruritus - Pipeline by Mirum Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Neurim Pharmaceuticals Ltd, 2022
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, 2022
Pruritus - Pipeline by Peptide Logic LLC, 2022
Pruritus - Pipeline by Pfizer Inc, 2022
Pruritus - Pipeline by RaQualia Pharma Inc, 2022
Pruritus - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Saniona AB, 2022
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2022
Pruritus - Pipeline by Shanton Pharma Co Ltd, 2022
Pruritus - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, 2022
Pruritus - Pipeline by Sunny Pharmtech Inc, 2022
Pruritus - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
Pruritus - Pipeline by Teikoku Pharma USA Inc, 2022
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Titan Pharmaceuticals Inc, 2022
Pruritus - Pipeline by Toray Industries Inc, 2022
Pruritus - Pipeline by Trevi Therapeutics Inc, 2022
Pruritus - Pipeline by Vivozon Inc, 2022
Pruritus - Pipeline by YIRUI Pharmaceutical Technology Co Ltd, 2022
Pruritus - Dormant Projects, 2022
Pruritus - Dormant Projects, 2022 (Contd..1)
Pruritus - Discontinued Products, 2022